BusinessFate Therapeutics Receives FDA Orphan Drug Designation for ProTmune™ in Allogeneic Hematopoietic Cell TransplantationBy Nasdaq OMXSep 26, 2016, 12:00 PM UTC
BusinessSummit Receives Fast Track Designation From US FDA for Ezutromid in the Treatment of Duchenne Muscular DystrophyBy Nasdaq OMXSep 26, 2016, 11:00 AM UTC
BusinessAkari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Paroxysmal Nocturnal HemoglobinuriaBy Nasdaq OMXSep 12, 2016, 11:15 AM UTC
BusinessPetLife Pharmaceuticals Hires InnoVision Therapeutics in Preparation of Vitalzul™ FDA SubmissionBy Nasdaq OMXAug 25, 2016, 12:43 PM UTC
BusinessSANUWAVE Announces 24-Week Data From Its Pivotal Trials Investigating the Use of dermaPACE for the Treatment of Diabetic Foot UlcersBy Nasdaq OMXMar 24, 2016, 1:00 PM UTC
BusinessU.S. Food and Drug Administration (FDA) Grants Breakthrough Therapy Designation to Immunomedics for Sacituzumab Govitecan for the Treatment of Patients With Triple-Negative Breast CancerBy Nasdaq OMXFeb 5, 2016, 2:28 PM UTC
